Human Trials

bluebird unveils topline interim data from Starbeam study of Lenti-D in CALD

bluebird bio has released topline interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating its investigational gene therapy Lenti-D in under-18 boys with cerebral adrenoleukodystrophy (CALD).

Roche’s emicizumab shows substantial reduction in bleeds in phase III studies

Roche’s haemophilia A drug emicizumab has showed a significant effect in the phase III Haven 1 and Haven 2 studies.

Novartis’ heart drug canakinumab meets primary endpoint in phase III study

Novartis’ heart drug ACZ885 (canakinumab) has met primary endpoint in the global phase III Canakinumab anti-inflammatory thrombosis outcomes (Cantos) study.

Pfizer initiates phase 1 study of streptococcus vaccine

Pfizer has commenced a phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine for the prevention of Group B Streptococcus (GBS) infection.

Centrexion’s pain drug CNTX-4975 yields positive results in phase 2b knee osteoarthritis trial

Centrexion Therapeutics reported positive 6-month efficacy data from the Phase 2b TRIUMPH trial demonstrating durable response of CNTX-4975 for treatment of chronic pain associated with knee osteoarthritis.

REMD’s lead candidate succeeds in phase 1 trial in type 1 diabetes patients

REMD Biotherapeutics (REMD Bio) and its subsidiary Cosci-REMD Biotherapeutics (Cosci-REMD Bi) have announced positive results from a phase 1 clinical study of its lead candidate REMD-477 in patients with type 1 diabetes.

Probiodrug unveils encouraging results of phase 2a SAPHIR study in AD patients

Probiodrug has reported positive results for its PQ912 candidate in a Phase 2a SAPHIR study in early Alzheimer’s disease (AD) patients.

Merck and Pfizer’s ertugliflozin meets primary endpoints in two type 2 diabetes studies

Merck, in partnership with Pfizer, announced that two phase 3 studies of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help enhance glycemic control in adults with type 2 diabetes, met their primary endpoints.

Teva’s migraine candidate fremanezumab succeeds in second phase III study

Teva Pharmaceutical Industries’ Fremanezumab has meets all primary & secondary endpoints across both monthly and quarterly dosing regimens in phase III study in episodic migraine prevention.